The GLP-1 market gets a lot of coverage. Eli Lilly, Novo Nordisk, the next oral pill, the next injection, the next headline. Most investors already have a view on the big names. What gets skipped in that conversation is the company that could walk into that market from the side door, with cleaner data and no baggage.
Viking Therapeutics (NASDAQ: VKTX) is not a household name. It doesn’t have a commercialized drug. It has something more specific right now: two fully enrolled Phase 3 trials, a Q3 data readout on the horizon, and a Wall Street consensus price target that implies significant upside from current levels.
The anti-obesity drug market is expected to grow from roughly $26 billion last year to more than $130 billion per year by 2031. That’s the context. What Viking is chasing is a slice of one of the fastest-expanding pharmaceutical markets ever recorded.
The Drug and Where It Stands
VK2735 is a wholly owned long-acting dual agonist of the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide, or GIP receptor, for the potential treatment of obesity and other metabolic disorders.
Both Phase 3 VANQUISH trials are now fully enrolled. Concurrently, Viking is conducting the Phase 3 VANQUISH-1 study of subcutaneous VK2735 in patients who have obesity or are overweight. Enrollment in VANQUISH-1 was completed in November 2025. VANQUISH-2 enrollment was completed in March 2026.
Top-line data from the prior Phase 2 VENTURE study of VK2735 were positive, with patients achieving statistically significant reductions in mean body weight from baseline, ranging up to 14.7% after 13 weekly doses. The study also showed VK2735 to be safe and well tolerated through 13 weeks of dosing, with the majority of treatment-emergent adverse events characterized as mild or moderate.
The stock has a habit of reacting violently to data. Viking stock has soared after positive data in the past, gaining 121% in one trading session after the Phase 2 report in February of 2024. Q3 maintenance dosing results could be that kind of moment again. Or they could disappoint. That’s the game with clinical-stage biotech.
The Differentiation Question
This is where it gets interesting. The obvious pushback is: Lilly and Novo are already here. Why does the market need another GLP-1?
There’s only so much differentiation that can be achieved using the same basic GLP-1 pathway. In the pharmaceutical business, though, when it comes to what people are willing to put in their bodies, little things can matter in a big way.
Viking is also developing VK2735 in an oral tablet formulation. The company’s planned Phase 3 studies with the oral tablet formulation are expected to begin later this year, with the goal of introducing the industry’s first oral and subcutaneous dual GLP-1 and GIP co-agonist molecule for the treatment of obesity.
An oral option changes the access conversation entirely. Some people simply don’t like needles and wouldn’t consider the once-a-week injection. A pill removes that barrier outright. If oral VK2735 data come in strong alongside the injectable readout, the competitive positioning shifts in ways that are hard to model from today’s numbers.
Slight tangent: starting mid-2026, Medicare will begin covering GLP-1 weight-loss drugs for select patient groups. That is a structural demand expansion that benefits every approved drug in this category, not just the ones already on the market. The timing is almost exactly when Viking’s data window opens.
The Honest Risk Picture
This is a clinical-stage company. There’s significant risk here, as is the case for any biopharma name that doesn’t yet have a revenue-bearing product on the market. Phase 3 trials fail. Data can be positive but not differentiated enough to matter commercially. Lilly and Novo have manufacturing scale, brand recognition, and physician relationships that Viking cannot match from a standing start.
The Q3 readout is not a guaranteed catalyst. It is a known catalyst with an uncertain outcome.
Concurrent with Phase 3 activities, the novel maintenance dosing trial continues, and data from that study are expected in the third quarter. That result is the one to watch. The market will likely move on it, one direction or the other, and the move could be large.
Whether you believe the bull case or not probably depends on how you think about clinical risk versus asymmetric upside. The setup is real. The outcome isn’t.
Disclaimer: This editorial is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Investing involves risk, including the possible loss of principal. Biopharmaceutical investments carry additional risks related to clinical trial outcomes, regulatory approvals, and commercialization uncertainty. Always conduct your own due diligence or consult a licensed financial advisor before making any investment decisions.
